
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 7)*

KALVISTA PHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock, \$0.001 par value per share

(Title of Class of Securities)

483497103

(CUSIP Number)

Steve R. Bailey
601 Union Street, Suite 3200,
Seattle, WA, 98101
(206) 621-7200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

11/01/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 483497103

Name of reporting person

1 Frazier Life Sciences Public Fund, L.P.

2 Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3 SEC use only
Source of funds (See Instructions)

4 WC
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 DELAWARE

Sole Voting Power

7

0.00

Number of Shares Beneficially

Shared Voting Power

Owned by Each Reporting Person

8

3,466,521.00

Sole Dispositive Power

9

0.00

With: Shared Dispositive Power

10

3,466,521.00

Aggregate amount beneficially owned by each reporting person

11 3,466,521.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12
Percent of class represented by amount in Row (11)

13 6.9 %

Type of Reporting Person (See Instructions)

14 PN

Comment for Type of Reporting Person: The shares listed in rows 8, 10 and 11 include shares that were acquired from Frazier Life Sciences Public Overage Fund, L.P. pursuant to a merger between Frazier Life Sciences Public Overage Fund, L.P. and Frazier Life Sciences Public Fund, L.P. The percentage listed in row 13 is calculated based on 50,523,274 shares of the Issuer's Common Stock outstanding as of August 29, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on September 11, 2025.

SCHEDULE 13D

CUSIP No. 483497103

Name of reporting person

1 FHMLSP, L.P.

Check the appropriate box if a member of a Group (See Instructions)

2 (a)

(b)

3 SEC use only
Source of funds (See Instructions)

4 AF

5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Citizenship or place of organization
6 DELAWARE
Sole Voting Power
7 0.00
Number of Shares Beneficially Owned by Each Reporting Person With: 8 Shared Voting Power
3,466,521.00
Sole Dispositive Power
9 0.00
Shared Dispositive Power
10 3,466,521.00
Aggregate amount beneficially owned by each reporting person
11 3,466,521.00
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12

Percent of class represented by amount in Row (11)
13 6.9 %
Type of Reporting Person (See Instructions)
14 PN

Comment for Type of Reporting Person: The shares listed in rows 8, 10 and 11 include shares that were acquired from Frazier Life Sciences Public Overage Fund, L.P. pursuant to a merger between Frazier Life Sciences Public Overage Fund, L.P. and Frazier Life Sciences Public Fund, L.P. The percentage listed in row 13 is calculated based on 50,523,274 shares of the Issuer's Common Stock outstanding as of August 29, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on September 11, 2025.

SCHEDULE 13D

CUSIP No. 483497103

1 Name of reporting person
FHMLSP, L.L.C.
Check the appropriate box if a member of a Group (See Instructions)
2 (a)
 (b)
3 SEC use only
Source of funds (See Instructions)
4 AF
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5

Citizenship or place of organization
6 DELAWARE
Number of Shares Beneficially Owned by 7 Sole Voting Power
0.00
8 Shared Voting Power

| | | |
|-----------------------------|--|--------------------------|
| Each Reporting Person With: | 3,466,521.00 | Sole Dispositive Power |
| | 9 | |
| | 0.00 | Shared Dispositive Power |
| | 10 | |
| | 3,466,521.00 | |
| 11 | Aggregate amount beneficially owned by each reporting person | |
| | 3,466,521.00 | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) | |
| | <input type="checkbox"/> | |
| 13 | Percent of class represented by amount in Row (11) | |
| | 6.9 % | |
| 14 | Type of Reporting Person (See Instructions) | |
| | OO | |

Comment for Type of Reporting Person: The shares listed in rows 8, 10 and 11 include shares that were acquired from Frazier Life Sciences Public Overage Fund, L.P. pursuant to a merger between Frazier Life Sciences Public Overage Fund, L.P. and Frazier Life Sciences Public Fund, L.P. The percentage listed in row 13 is calculated based on 50,523,274 shares of the Issuer's Common Stock outstanding as of August 29, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on September 11, 2025.

SCHEDULE 13D

CUSIP No. 483497103

| | | |
|--|---|--|
| 1 | Name of reporting person | |
| | Frazier Life Sciences X, L.P. | |
| | Check the appropriate box if a member of a Group (See Instructions) | |
| 2 | <input type="checkbox"/> (a) | |
| | <input checked="" type="checkbox"/> (b) | |
| 3 | SEC use only | |
| 4 | Source of funds (See Instructions) | |
| | WC | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) | |
| | <input type="checkbox"/> | |
| 6 | Citizenship or place of organization | |
| | DELAWARE | |
| | Sole Voting Power | |
| 7 | | |
| | 0.00 | |
| Number of Shares Beneficially Owned by Each Reporting Person With: | Shared Voting Power | |
| 8 | | |
| | 1,160,700.00 | |
| | Sole Dispositive Power | |
| 9 | | |
| | 0.00 | |
| | Shared Dispositive Power | |
| 10 | | |
| | 1,160,700.00 | |

11 Aggregate amount beneficially owned by each reporting person
 1,160,700.00
 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12
 Percent of class represented by amount in Row (11)

13 2.3 %
 Type of Reporting Person (See Instructions)

14 PN

Comment for The percentage listed in row 13 is calculated based on 50,523,274 shares of the Issuer's Common Stock
Type of Reporting Person: outstanding as of August 29, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on September 11, 2025.

SCHEDULE 13D

CUSIP No. 483497103

1 Name of reporting person
 FHMLS X, L.P.
 Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
 Source of funds (See Instructions)

4 AF
 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
 Citizenship or place of organization

6 DELAWARE

7 Sole Voting Power
 0.00

Number of Shares Beneficially Owned by Each Reporting Person With: 8 Shared Voting Power
 1,160,700.00

9 Sole Dispositive Power
 0.00

10 Shared Dispositive Power
 1,160,700.00

11 Aggregate amount beneficially owned by each reporting person
 1,160,700.00
 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12
 Percent of class represented by amount in Row (11)

13 2.3 %

14 Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person: The percentage listed in row 13 is calculated based on 50,523,274 shares of the Issuer's Common Stock outstanding as of August 29, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on September 11, 2025.

SCHEDULE 13D

CUSIP No. 483497103

1 Name of reporting person
 FHMLS X, L.L.C.
 Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
 Source of funds (See Instructions)

4 AF
 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
 Citizenship or place of organization

6 DELAWARE
 Sole Voting Power

7 0.00
 Number of Shares Beneficially Owned by Each Reporting Person With:
 Shared Voting Power

8 1,160,700.00
 Sole Dispositive Power

9 0.00
 Shared Dispositive Power

10 1,160,700.00
 Aggregate amount beneficially owned by each reporting person

11 1,160,700.00
 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12
 Percent of class represented by amount in Row (11)

13 2.3 %
 Type of Reporting Person (See Instructions)

14 OO

Comment for Type of Reporting Person: The percentage listed in row 13 is calculated based on 50,523,274 shares of the Issuer's Common Stock outstanding as of August 29, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on September 11, 2025.

1 Name of reporting person
Frazier Life Sciences XI, L.P.
Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4 WC
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

6 Citizenship or place of organization
DELAWARE

7 Sole Voting Power
0.00

Number of Shares Beneficially Owned by Each Reporting Person With:

8 Shared Voting Power
394,847.00

9 Sole Dispositive Power
0.00

10 Shared Dispositive Power
394,847.00

11 Aggregate amount beneficially owned by each reporting person
394,847.00

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)
0.8 %

14 Type of Reporting Person (See Instructions)
PN

Comment for Type of Reporting Person: The percentage listed in row 13 is calculated based on 50,523,274 shares of the Issuer's Common Stock outstanding as of August 29, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on September 11, 2025.

SCHEDULE 13D

1 Name of reporting person
FHMLS XI, L.P.
Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4 AF
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 DELAWARE

7 Sole Voting Power

Number of Shares Beneficially Owned by Each Reporting Person With: 8 0.00
Shared Voting Power

9 394,847.00
Sole Dispositive Power

10 0.00
Shared Dispositive Power

11 394,847.00
Aggregate amount beneficially owned by each reporting person

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13
Percent of class represented by amount in Row (11)

14 0.8 %
Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 13 is calculated based on 50,523,274 shares of the Issuer's Common Stock outstanding as of August 29, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on September 11, 2025.

SCHEDULE 13D

CUSIP No. 483497103

1 Name of reporting person
FHMLS XI, L.L.C.
Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4 AF
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 DELAWARE

| | | |
|--|------------|--|
| Number of Shares Beneficially Owned by Each Reporting Person With: | 7 | Sole Voting Power |
| | 0.00 | |
| | | Shared Voting Power |
| | 8 | |
| | 394,847.00 | |
| | | Sole Dispositive Power |
| | 9 | |
| | 0.00 | |
| | | Shared Dispositive Power |
| | 10 | |
| | 394,847.00 | |
| | | Aggregate amount beneficially owned by each reporting person |
| 11 | | 394,847.00 |
| 12 | | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) |
| | | <input type="checkbox"/> |
| | | Percent of class represented by amount in Row (11) |
| 13 | | 0.8 % |
| | | Type of Reporting Person (See Instructions) |
| 14 | | OO |

Comment for Type of Reporting Person: The percentage listed in row 13 is calculated based on 50,523,274 shares of the Issuer's Common Stock outstanding as of August 29, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on September 11, 2025.

SCHEDULE 13D

CUSIP No. 483497103

| | |
|---|---|
| 1 | Name of reporting person |
| | James N. Topper |
| | Check the appropriate box if a member of a Group (See Instructions) |
| 2 | <input type="checkbox"/> (a) |
| | <input checked="" type="checkbox"/> (b) |
| 3 | SEC use only |
| 4 | Source of funds (See Instructions) |
| | AF |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) |
| | <input type="checkbox"/> |
| 6 | Citizenship or place of organization |
| | UNITED STATES |

| | | |
|--|--------------|-----------------------------|
| Number of Shares Beneficially Owned by Each Reporting Person With: | 7 | Sole Voting Power |
| | 0.00 | |
| | | Shared Voting Power |
| | 8 | |
| | 1,160,700.00 | |
| | | Sole Dispositive Power |
| | 9 | |
| | 0.00 | |
| | | 10 Shared Dispositive Power |

1,160,700.00

Aggregate amount beneficially owned by each reporting person

11

1,160,700.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

2.3 %

Type of Reporting Person (See Instructions)

14

IN

Comment for Type of Reporting Person:

The shares listed in rows 8, 10 and 11 represent shares of Common Stock held directly by Frazier Life Sciences X, L.P. The percentage listed in row 13 is calculated based on 50,523,274 shares of the Issuer's Common Stock outstanding as of August 29, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on September 11, 2025.

SCHEDULE 13D

CUSIP No. 483497103

Name of reporting person

1

Patrick J. Heron

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

AF

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

UNITED STATES

Sole Voting Power

7

0.00

Number of Shares Beneficially Owned by Each Reporting Person With:

Shared Voting Power

8

1,160,700.00

Sole Dispositive Power

9

0.00

Shared Dispositive Power

10

1,160,700.00

Aggregate amount beneficially owned by each reporting person

11

1,160,700.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

2.3 %

Type of Reporting Person (See Instructions)

14

IN

Comment for Type of Reporting Person: The shares listed in rows 8, 10 and 11 represent shares of Common Stock held directly by Frazier Life Sciences X, L.P. The percentage listed in row 13 is calculated based on 50,523,274 shares of the Issuer's Common Stock outstanding as of August 29, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on September 11, 2025.

SCHEDULE 13D

Item 1. Security and Issuer

Title of Class of Securities:

(a)

Common Stock, \$0.001 par value per share

Name of Issuer:

(b)

KALVISTA PHARMACEUTICALS, INC.

Address of Issuer's Principal Executive Offices:

(c)

55 Cambridge Parkway, Suite 901E, Cambridge, MASSACHUSETTS , 02142.

Item 1 Comment: This Amendment No. 7 ("Amendment No. 7") to Schedule 13D amends the statement on Schedule 13D filed on December 30, 2021 (the "Original Schedule 13D") as amended on January 26, 2022, December 30, 2022, December 14, 2023, February 22, 2024, November 7, 2024 and August 20, 2025 (the "Prior Amendments", and together with the Original Schedule 13D and this Amendment No. 7, the "Schedule 13D"). Except as otherwise specified in Amendment No. 7, all items in the Original Schedule 13D, as amended by the Prior Amendments, are unchanged. All capitalized terms used in this Amendment No. 7 and not otherwise defined herein have the meanings ascribed to such terms in the Original Schedule 13D, as amended by the Prior Amendments.

Item 2. Identity and Background

The entities and persons filing this statement (collectively, the "Reporting Persons") are: Frazier Life Sciences Public Fund, L.P. ("FLSPF") FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences X, L.P. ("FLS X") FHMLS X, L.P. FHMLS X, L.L.C. Frazier Life Sciences XI, L.P. ("FLS XI") FHMLS XI, L.P. FHMLS XI, L.L.C. James N. Topper ("Topper") Patrick J. Heron ("Heron" and together with Topper, the "Members")

Item 2(c) is hereby amended and restated in its entirety to read as follows: FLSPF is a venture capital fund concentrating in life sciences and related fields. The sole business of FHMLSP, L.P. is to serve as general partner of FLSPF. The sole business of FHMLSP, L.L.C. is to serve as general partner of FHMLSP, L.P. FLS X is a venture capital fund concentrating in life sciences and related fields. The sole business of FHMLS X, L.P. is to serve as general partner of FLS IX. The sole business of FHMLS X, L.L.C. is to serve as general partner of FHMLS X, L.P. FLS XI is a venture capital fund concentrating in life sciences and related fields. The sole business of FHMLS XI, L.P. is to serve as general partner of FLS XI. The sole business of FHMLS XI, L.L.C. is to serve as general partner of FHMLS XI, L.P. The principal business of the Members is to manage FLSPF, FHMLSP, L.P., FHMLSP, L.L.C., FLS X, FHMLS X, L.P., FHMLS X, L.L.C., FLS XI, FHMLS XI, L.P., FHMLS XI, L.L.C. and a number of affiliated partnerships with similar businesses.

Item 3. Source and Amount of Funds or Other Consideration

Item 3 of the Schedule 13D is hereby amended to incorporate Item 5(c) hereof and to replace the last paragraph with the following: The working capital of FLSPF, FLS X and FLS XI was the source of the funds for the purchase of the FLSPF Shares, the FLS X Shares and the FLS XI Shares. No part of the purchase price of the FLSPF Shares, the FLS X Shares or the FLS XI Shares was represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting the FLSPF Shares, the FLS X Shares or the FLS XI Shares.

Item 4. Purpose of Transaction

Item 4 is hereby amended and restated in its entirety to read as follows: The Reporting Persons acquired the Common Stock for investment purposes. Unless otherwise noted in this Schedule 13D, no Reporting Person has any current plans or proposals, which related to, or would result in, any of the matters referred to in paragraphs (a) through (j), inclusive of Item 4 of Schedule 13D. The Reporting Persons may, at any time and from time to time, review or reconsider their positions and formulate plans or proposals with respect thereto, including, without limitation, the acquisition of additional shares of Common Stock. The Reporting Persons may dispose of any or all the shares of Common Stock they hold.

Item 5. Interest in Securities of the Issuer

(a)

The information contained in Rows 7, 8, 9, 10, 11, and 13 of each Reporting Person's cover page to this Schedule 13D (including the footnotes thereto) is incorporated by reference into this Item 5. FLSPF directly holds 3,466,521

shares of the Issuer's Common Stock (the "FLSPF Shares"). FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF. FLS X directly holds 1,160,700 shares of the Issuer's Common Stock (the "FLS X Shares"). FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the FLS X Shares. FLS XI directly holds 394,847 shares of this Issuer's Common Stock (the "FLS XI Shares"). FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI. Except as specifically stated herein, the filing of this Schedule 13D shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Schedule 13D or a member of a "group" with any other person.

(c) Except as set forth in Item 6 hereof, none of the Reporting Persons has effected any transactions relating to the Common Stock of the Issuer during the past 60 days.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

On November 1, 2025, FLSPF and Frazier Life Sciences Public Overage Fund, L.P. ("FLSPOF") entered into a merger agreement, which resulted in FLSPOF merging with and into FLSPF. As a result of the merger, (i) FLSPF acquired 973,449 shares of Common Stock of the Issuer from FLSPOF and (ii) FLSPOF, FHMLSP Overage, L.P., FHMLSP Overage, L.L.C. ceased being Reporting Persons under the Schedule 13D.

Item 7. Material to be Filed as Exhibits.

Exhibit 99.1 Joint Filing Agreement

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Frazier Life Sciences Public Fund, L.P.

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.

Date: 11/04/2025

FHMLSP, L.P.

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.

Date: 11/04/2025

FHMLSP, L.L.C.

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, CFO of FHMLSP, L.L.C.

Date: 11/04/2025

Frazier Life Sciences X, L.P.

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.

Date: 11/04/2025

FHMLS X, L.P.

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.

Date: 11/04/2025

FHMLS X, L.L.C.

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, CFO of FHMLS X, L.L.C.

Date: 11/04/2025

Frazier Life Sciences XI, L.P.

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, CFO of FHMLS XI, L.L.C.,
GP of FHMLS XI, L.P., GP of Frazier Life
Sciences XI, L.P.

Date: 11/04/2025

FHMLS XI, L.P.

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, CFO of FHMLS XI, L.L.C.,
GP of FHMLS XI, L.P.

Date: 11/04/2025

FHMLS XI, L.L.C.

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, CFO of FHMLS XI, L.L.C.

Date: 11/04/2025

James N. Topper

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, Attorney-in-Fact for James N.
Topper, pursuant to a Power of Attorney, a copy
of which was filed with the SEC on July 31, 2017

Date: 11/04/2025

Patrick J. Heron

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, Attorney-in-Fact for Patrick J.
Heron, pursuant to a Power of Attorney, a copy of
which was filed with the SEC on July 31, 2017

Date: 11/04/2025

JOINT FILING AGREEMENT

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Shares of Common Stock of KalVista Pharmaceuticals, Inc.

Date: November 4, 2025

FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.

By: FHMLSP, L.P., its General Partner

By: FHMLSP, L.L.C., its General Partner

By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

Date: November 4, 2025

FHMLSP, L.P.

By: FHMLSP, L.L.C., its General Partner

By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

Date: November 4, 2025

FHMLSP, L.L.C.By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

Date: November 4, 2025

FRAZIER LIFE SCIENCES X, L.P.

By: FHMLS X, L.P., its General Partner

By: FHMLS X, L.L.C., its General Partner

By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

Date: November 4, 2025

FHMLS X, L.P.

By: FHMLS X, L.L.C., its General Partner

By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

Date: November 4, 2025

FHMLS X, L.L.C.By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

Date: November 4, 2025

FRAZIER LIFE SCIENCES XI, L.P.

By: FHMLS XI, L.P., its General Partner

By: FHMLS XI, L.L.C., its General Partner

By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

Date: November 4, 2025

FHMLS XI, L.P.

By: FHMLS XI, L.L.C., its General Partner

By: /s/ Steve R. Bailey

Steve R. Bailey, Chief Financial Officer

Date: November 4, 2025

FHMLS XI, L.L.C.

By: /s/ Steve R. Bailey
Steve R. Bailey, Chief Financial Officer

Date: November 4, 2025

By: *
James N. Topper

Date: November 4, 2025

By: *
Patrick J. Heron

Date: November 4, 2025

By: /s/ Steve R. Bailey
Steve R. Bailey, as Attorney-in-Fact

* This Joint Filing Agreement was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017.